Md. Selim Reza*, Farzana Mim, Dr. Mohammad Rezaul Quader,Dr. Mohammad Jahidur Rahman Khan, Md. Sabir Hossain, Kazi Rasel Uddin, Salina Akter and Dr. Sharmin Rahman


Severe acute respiratory syndrome (SARS) is an emerging infectious disease caused by SARS–associated coronavirus (SARS-CoV). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is another new type of coronavirus that causes the Coronavirus Disease 2019 (COVID-19), which has been the most challenging pandemic in this century. SARS-CoV-2 which is genetically similar to SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV) is an enveloped, single and positive-stranded RNA virus. Considering its high mortality and rapid spread, an effective vaccine is urgently needed to control this pandemic. Vaccines, such as inactivated vaccines, attenuated vaccines, nucleic acid-based vaccines, and vector vaccines, which have already been demonstrated their prophylactic efficacy against MERS-CoV and SARS-CoV, so these candidates could be used as a potential tool for the development of a safe and effective vaccine against SARS-CoV-2. The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS-CoV-2 vaccines.

Keywords: Corona virus; Pandemic; SARS-CoV-2; COVID-19; MERS-CoV; Vaccine.

[Full Text Article]


Forgot Password  |  Register


Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation


    MAY 2023 Issue has been successfully launched on 1 MAY 2023.

  • EJBPS New Impact Factor

    Its our Pleasure to Inform you that EJBPS Impact Factor has been increased from 5.467 to 6.044, due to high quality Publication at International Level.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.


UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS


Copyright From

Covering Letter

                        Author Instruction